Purpose of this Study
This study has three parts:
- Screening (up to 21 days): You'll get health checks like heart tests, scans, and blood work.
- Study Drug Period (28-day cycles): You'll be randomly placed in one of two groups:
- One group gets AZD3632 alone.
-The other gets AZD3632 with another medicine called posaconazole. You'll have regular visits for tests and questions.
- After Treatment: You'll have a safety check 30 days after your last dose, then visits every 12 weeks to see how your disease is doing.
Who Can Participate?
Eligibility
Adults with certain blood cancers; like AML, ALL, MPAL, AUL, or MDS—can join this study. Some parts of the study are for people whose cancer has come back, which means there are more than 5% cancer cells in their bone marrow again.
Age Range
18-100
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
This study is being done to see if a new medicine called AZD3632 is safe and works well for people with certain blood cancers called acute leukemia or MDS.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants with Advanced Haematologic Malignancies with KMT2Ar, NPM1m, or Other Genotypes Associated with HOX Overexpression
Principal Investigator
Harry
Erba
Protocol Number
PRO00118800
NCT ID
NCT07155226
Phase
I/II
Enrollment Status
Pending Open to Enrollment